Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Basic): 2012-2025

Historic EPS (Basic) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$1.78.

  • Agios Pharmaceuticals' EPS (Basic) fell 110.69% to -$1.78 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.98, marking a year-over-year decrease of 159.20%. This contributed to the annual value of $11.86 for FY2024, which is 287.36% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' EPS (Basic) stood at -$1.78, which was up 7.77% from -$1.93 recorded in Q2 2025.
  • Agios Pharmaceuticals' EPS (Basic)'s 5-year high stood at $26.95 during Q1 2021, with a 5-year trough of -$1.93 in Q2 2025.
  • Its 3-year average for EPS (Basic) is $0.02, with a median of -$1.64 in 2023.
  • Per our database at Business Quant, Agios Pharmaceuticals' EPS (Basic) soared by 2,291.06% in 2021 and then crashed by 356.72% in 2023.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' EPS (Basic) stood at -$1.81 in 2021, then skyrocketed by 137.02% to $0.67 in 2022, then plummeted by 356.72% to -$1.72 in 2023, then declined by 0.00% to -$1.72 in 2024, then slumped by 110.69% to -$1.78 in 2025.
  • Its EPS (Basic) stands at -$1.78 for Q3 2025, versus -$1.93 for Q2 2025 and -$1.55 for Q1 2025.